CD47 and cancer: revealed that compared to wild-type and signal regulatory protein α knockout mice, CD47 knockout mice had reduced red blood cell counts and hemoglobin levels, suggesting that selectively blocking signal regulatory protein α (SIRP α )-mediated signaling could circumvent the hematological side effects of using CD47-Ab, making it an effective ICI treatment strategy for cancer patients at high risk of atherosclerosis.